健民集团（600976）8月5日主力资金净流出1154.61万元

Group 1 - The core viewpoint of the news is that Jianmin Group's recent financial performance shows a decline in revenue but an increase in net profit, indicating potential resilience in profitability despite revenue challenges [1] - As of August 5, 2025, Jianmin Group's stock closed at 42.11 yuan, down 0.64%, with a turnover rate of 2.25% and a trading volume of 34,400 hands, amounting to a transaction value of 145 million yuan [1] - The latest quarterly report indicates that the company's total operating revenue was 892 million yuan, a year-on-year decrease of 8.04%, while the net profit attributable to shareholders was 110 million yuan, a year-on-year increase of 10.70% [1] Group 2 - The company has a current ratio of 1.646, a quick ratio of 1.456, and a debt-to-asset ratio of 40.15%, reflecting a stable liquidity position [1] - Jianmin Pharmaceutical Group Co., Ltd. was established in 1993 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of 1.533986 billion yuan [1] - The company has made investments in 30 enterprises and has participated in 5,000 bidding projects, showcasing its active engagement in the market [2]